Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results (SABCS 2025) - Oct 31, 2025 - Abstract #PD13-04; Pres time: Dec 12, 2025; 07:39 AM - 07:42 AM; Location: Hemisfair 3; "Reyobiq shows excellent safety and promising activity for LM. A single dose for patients with LM was well-tolerated up to the RP2D of 44.10 mCi, with high absorbed doses to the treatment area, acceptable organ doses, and encouraging response and reductions in tumor cell count. Within the breast cancer patients, response rate and survival were also promising."
P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Triple Negative Breast Cancer • ER • HER-2 • PGR
|
|
A. Brenner1; M. Youssef2; P. Kumthekar3; M. Schulder4; J. Floyd5; A. Bao6; W. Phillips7; P. Vroman7; J. Michalek8; M. Moore9; M. Rosol10; M. Hedrick10
|